Insider buying
~$5.9K10K sh @ $0.59
Traded Nov 17 · filed 1 day later
Compass Therapeutics's Chief Accounting Officer paid $5.9K out of pocket for Compass Therapeutics shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CMPX · NASDAQ · Biological Products, (No Diagnostic Substances)
Compass Therapeutics (CMPX) · oqro.io/stocks/CMPX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.6067−0.0548 (−8.28%)
Close of Nov 17, 2026, vs Nov 16 · end-of-day, not a live quote
19 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Insider buying
Traded Nov 17 · filed 1 day later
Compass Therapeutics's Chief Accounting Officer paid $5.9K out of pocket for Compass Therapeutics shares.
Insider buying
Traded Oct 1 · filed 1 day later
Since the trade −32.7% · S&P 500 −4.1% · to Nov 17
Compass Therapeutics's Chief Accounting Officer paid $18K out of pocket for Compass Therapeutics shares. Shares held went up 5% with this purchase.
Insider buying
Traded Sep 24 · filed 1 day later
Since the trade −46.5% · S&P 500 −4.5% · to Nov 17
Compass Therapeutics's Chief Accounting Officer paid $2.9K out of pocket for Compass Therapeutics shares.
Insider buying
6 days before resultsTraded Apr 29 · filed 1 day later
Since the trade −63.7% · S&P 500 +2.9% · to Nov 17
Compass Therapeutics's General Counsel paid $47K out of pocket for Compass Therapeutics shares. 1 other person at Compass Therapeutics bought some too, in the same month. Shares held went up 15% with this purchase.
Insider buying
6 days before resultsTraded Apr 29 · filed 1 day later
Since the trade −63.7% · S&P 500 +2.9% · to Nov 17
Compass Therapeutics's Chief Accounting Officer paid $28K out of pocket for Compass Therapeutics shares. 1 other person at Compass Therapeutics bought some too, in the same month.
Insider buying
Traded May 27, 2025 · filed the same day
Since the trade −71.3% · S&P 500 +23.9% · to Nov 17
The CEO of Compass Therapeutics paid $21K out of pocket for Compass Therapeutics shares.
Insider selling
Traded Apr 9, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −65.3% · S&P 500 +33.5% · to Nov 17
A Compass Therapeutics director sold $5.68M of Compass Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Apr 9, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −65.3% · S&P 500 +33.5% · to Nov 17
A Compass Therapeutics director sold $5.68M of Compass Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Apr 7, 2025 · filed 1 day later
Since the trade −61.4% · S&P 500 +45.2% · to Nov 17
Compass Therapeutics's Gen Counsel & Corporate Sec paid $31K out of pocket for Compass Therapeutics shares. 1 other person at Compass Therapeutics bought some too, in the same month. Shares held went up 2000% with this purchase.
Insider buying
Traded Apr 7, 2025 · filed 1 day later
Since the trade −61.4% · S&P 500 +45.2% · to Nov 17
Compass Therapeutics's CHIEF ACCOUNTING OFFICER paid $28K out of pocket for Compass Therapeutics shares. 1 other person at Compass Therapeutics bought some too, in the same month. Shares held went up 7% with this purchase.
5 open-market purchases and 0 open-market sales by insiders of CMPX between Feb 3, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 9, 2026. The data provider lists the next release for Mar 3, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 9, 2026 | None | None | 1 purchase |
| Aug 6, 2026 | None | None | None |
| May 5, 2026 | 2 purchases | None | None |
| Mar 5, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies